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Objective: To examine the efficacy of different radiation doses after achievement of a complete response to
chemotherapy in diffuse large B-cell lymphoma (DLBCL).
Methods: Patients with stage I-IV DLBCL treated from 1995–2009 at Duke Cancer Institute who achieved a
complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were
calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered
radiation dose.
Results: 105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP
(65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT
(1%), or CT only (11%). The median RT dose was 30 Gy (range, 12–40 Gy). The median radiation dose was higher
for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p< 0.001).
Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%),
84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at
10 sites, without a clear dose response. In-field failure was higher at sites≥ 10 cm (14% versus 4%, p = 0.06).
Conclusion: In-field control was excellent with a combined modality approach when a complete response was
achieved after chemotherapy without a clear radiation dose response.Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon subtype of non-Hodgkin lymphoma. The initial
treatment is combination chemotherapy, most com-
monly consisting of the anti-CD20 antibody rituximab
combined with cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (R-CHOP). Rituximab improves
both event-free and overall survival in patients with
DLBCL.
After chemotherapy alone, the most common site of
disease recurrence is at sites of initial disease involvement
[1]. Most randomized trials [1-3], but not all, have shown
that consolidation radiation therapy (RT) decreases the
risk of disease recurrence in stage I-II DLBCL after* Correspondence: jdorth@gmail.com
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reproduction in any medium, provided the orCHOP chemotherapy. Both randomized [4,5] and retro-
spective [6,7] studies have also suggested a benefit in se-
lect patients with advanced disease. These studies predate
the widespread use of rituximab as well as positron emis-
sion tomography (PET), which is often performed after
chemotherapy to assess response. However, a large, retro-
spective analysis from MD Anderson suggested that con-
solidation RT also improves outcomes in patients of all
stages who achieve a complete response by PET with R-
CHOP [8]. Additionally, we reported a retrospective ana-
lysis demonstrating improved outcomes in patients with
stage III-IV DLBCL (65% received R-CHOP) treated with
consolidation RT after achieving negative post-
chemotherapy imaging (PET/CT in 73%) [9].
The optimal RT dose for patients who achieve a
complete response to R-CHOP chemotherapy based on
PET imaging is unknown. The randomized trials described
above employed RT doses ranging from 30–55 Gy and
were conducted prior to the use of rituximab and PETtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rituximab and PET imaging, directly compared different
RT doses in DLBCL and found no difference between 30
versus 40–45 Gy relating to in-field control or event-free
survival [10].
At Duke Cancer Institute (DCI), our general approach
for patients with stage I-II DLBCL is to treat with con-
solidation RT to all sites of initial disease involvement
with a minimum of 30 Gy, since that dose has curative
potential even if chemotherapy is ineffective [11]. For
stage III-IV disease, select patients receive consolidation
RT to either all sites of original involvement or to select
sites (e.g. large tumor masses), if treatment of all sites is
impractical. Lower doses of consolidation RT are typic-
ally used for advanced stage DLBCL (20–30 Gy) at DCI.
The rationale is that patients with advanced DLBCL typ-
ically receive more cycles of chemotherapy than those
with early-stage disease, allowing for a lower dose of con-
solidation radiation therapy. Further, with more wide-
spread disease necessitating larger treatment volumes,
the dose of RT is lowered to minimize toxicity. Finally, if
chemotherapy hasn’t been sufficiently effective, higher
doses of radiation are unlikely to make up the difference,
which differs from early-stage disease where RT alone is a
potentially curative modality.
It is quite possible that consolidation RT doses less
than 30 Gy confer equivalent in-field control in patients
who achieve a complete response to chemotherapy with
rituximab. In order to investigate this hypothesis further,
herein we report a retrospective dose–response analysis.
Methods
This DCI Institutional Review Board-approved study
reviewed all patients who were treated for stage I-IV
DLBCL between 1995 and 2009 at DCI who achieved a
complete response to combination chemotherapy and
were treated with consolidation radiation. These years
were selected as the time period during which post-
chemotherapy radiologic assessment became routine.
Patients with refractory disease or who did not achieve a
complete response were excluded. Additionally, patients
with central nervous system involvement were also
excluded.
The diagnosis of DLBCL was confirmed by hemato-
pathologists at DCI according to the WHO classification
[12]. Initial work up generally included computed tom-
ography (CT), gallium and/or positron emission tomog-
raphy (PET), bone marrow biopsy and lactate
dehydrogenase (LDH) and other routine blood studies.
Staging was based on the Ann Arbor classification [13].
The International Prognostic Index (IPI) was calculated
for all patients (age, performance status, extranodal in-
volvement, stage, and LDH) [14]. Patients received a var-
iety of chemotherapy regimens including CHOP, CNOP(cyclophosphamide, mitoxantrone, vincristine, and pred-
nisone) or other, with or without rituximab. All patients
had imaging performed to assess response to chemother-
apy (during and/or after completion of chemotherapy).
Gallium scans were performed during the early years
of the study period. Planar whole body and single pho-
ton emission computed tomography scans of the chest
and abdomen were obtained 72 or 96 hours after the
intravenous administration of 8 mCi of Ga-67 citrate.
PET imaging subsequently supplanted gallium scans.
From 1996–2003, PET scans were performed on a GE
Advance scanner (General Electric Medical Systems,
Milwaukee, WI) and the PET images were reviewed with
a concurrent CT. From 2003–2009, a Discovery ST
PET/CT scanner (General Electric Healthcare) was used
and the PET images were reviewed with the non-
contrast-enhanced CT.
Post-chemotherapy functional imaging studies were
interpreted by attending nuclear medicine radiologists
and were scored as positive or negative based on visual
analysis alone, in agreement with the consensus recom-
mendations of the International Harmonization Project
in Lymphoma [15]. Post-chemotherapy CT scans were
interpreted as negative if there were no sites of residual
lymphadenopathy greater than 1 cm. Patients achieving
a negative interim PET/gallium scan did not routinely
have functional imaging performed at the completion of
chemotherapy. All patients who had a positive interim
PET/gallium scan had an additional study performed at
least 2 weeks after the last cycle of chemotherapy.
Patients received consolidation RT at the discretion of
the treating medical and radiation oncologists. All
patients were treated with photon energies of 4–15 MV.
Consolidation RT was given 3–4 weeks after finishing
chemotherapy to originally involved sites plus an appro-
priate margin, without specifically targeting clinically un-
involved sites [16].
Statistical analysis
Actuarial in-field control, event-free survival and overall
survival were calculated using the Kaplan-Meier product
limit method [17]. Five-year survival estimates with 95%
confidence intervals (CI) were calculated. In-field local
control was defined as the absence of disease recurrence
within the previously-administered RT field, timed from
the date of completion of radiotherapy. Patients without
an in-field progression were censored at the time of dis-
tant failure, death, or last follow-up date. Event-free sur-
vival was defined as the time from completion of
chemotherapy until lymphoma progression or death as a
result of any cause, whichever occurred first. Alive
patients without progression were censored at date of
last follow-up. Overall survival was defined as the time
from completion of chemotherapy until death as a result
Table 1 Patient characteristics
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at the date of last follow-up. Categorical patient charac-
teristics were compared using the chi-square test; con-
tinuous patient characteristics were compared using the
Wilcoxon Rank-Sum test.
Given that most patients had multiple sites of disease
involvement at diagnosis, and sites sometimes received
different prescribed radiation doses, an analysis was con-
ducted by disease site. Sites were delineated based on
definitions of the standard involved field [16]. Radiation
dose bins were in 5 Gy increments, ranging from
≤20 Gy to 36–40 Gy.
Results
Between 1995 and 2009, 174 patients were identified
who were treated with radiation for stage I-IV DLBCL at
DCI. The following patients were excluded from the
present analysis: 5 treated for relapsed or refractory dis-
ease, 25 with a partial response to chemotherapy by
PET/gallium, 10 without post-chemotherapy imaging,
and 29 with central nervous system involvement. There-
fore, 105 patients treated to 214 sites were identified
who met the inclusion criteria.
Patient characteristics can be found in Table 1. Most
patients had stage I-II disease (69%). Chemotherapy pri-
marily consisted of R-CHOP (65%), but other regimens
were also utilized. The median number of chemotherapy
cycles was 6 (interquartile range, 4–6). Post-chemotherapy
imaging consisted of PET/CT in 88%, gallium and CT in
1%, and CT only in 11% of patients.
Radiation therapy was administered in 1.8 – 2 Gy frac-
tions to a median dose of 30 Gy, ranging from 12 –
40 Gy. The median radiation dose was higher for patients
with stage I-II disease compared with patients with stage
III-IV disease (30 versus 24.5 Gy, p< 0.001).
Overall outcomes
After a median follow-up for the alive patients of 5 years
(IQR, 3–8 years), 13 patients relapsed. Five-year in-field
control, event-free survival, and overall survival for all
patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92
%), and 91% (95% CI: 85-97%), respectively (Figure 1).
Among patients who relapsed, 2 relapsed only at
initially-involved sites (stage I-II: n = 1; stage III-IV:
n = 1), 8 at uninvolved sites (stage I-II: n = 5; stage III-IV:
n = 3), and 3 in both involved and uninvolved sites (stage
I-II: n = 2; stage III-IV: n = 1).
Dose response analysis
Disease sites receiving lower doses of RT generally
belonged to patients with higher IPI scores, reflecting
the fact that lower RT doses were typically used for
patients with advanced disease. The median IPI scorewas 2 among sites receiving 20 Gy, compared to 1
among sites receiving 30 Gy.
Prescribed radiation doses to individual sites and in-
field failures can be found in Table 2. Crude rates of
local failure ranged from 0% to 6% without a clear dose
response. Local recurrence appeared higher for sites
≥10 cm (14% versus 4%, p = 0.06). Patients with larger
tumors who experienced in-field failure were treated
with doses ≤ 30 Gy, but the number of events in each
dose bin was small (Table 2).
Discussion
Randomized and retrospective studies have shown that
consolidation RT significantly decreases the risk of dis-
ease recurrence in DLBCL, though most were not pow-
ered to detect an improvement in overall survival [1-8].
Given that many patients with DLBCL are long-term
survivors, optimizing disease control while minimizing
acute and late side effects is critical. The risk of RT-
induced late effects, including development of secondary
Figure 1 In-Field Control, Event-Free Survival and Overall
Survival.
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related to the total dose utilized and volume treated
[18].
The optimal RT dose for patients who have a complete
response to R-CHOP chemotherapy based on PET im-
aging remains unknown. A randomized trial from the
United Kingdom found excellent in-field control rates
with RT doses as low as 30 Gy [10]. It is possible that
RT doses less than 30 Gy are equally effective. Thus, we
evaluated our own experience in patients with DLBCL
treated predominantly with R-CHOP and all having
negative post-chemotherapy imaging (88% assessed with
PET). In this patient population, we observed excellent
in-field control with lower doses of RT. Additionally, a
relationship between RT dose and in-field control was
not evident.
In the study from the UK, 640 patients with
intermediate-to-high grade NHL (DLBCL: 85%; stage I-
II: 86%) were randomized to 30 Gy versus 40–45 Gy
[10]. Eighty percent of patients received consolidation
RT as part of a primary combined-modality regimen,Table 2 In-Field Failures by Dose*
Dose group ≤ 20 Gy 21-25 Gy 26-30 Gy 31-35 Gy 36-40 Gy
Total sites, n 77 17 81 35 4
Sites failed, n (%) 5 (6%) 0 (0%) 4 (5%) 1 (3%) 0 (0%)
Subgroups
< 10 cm
Total sites, n 67 15 74 31 3
Sites failed, n (%) 3 (4%) 0 (0%) 2 (3%) 1 (3%) 0 (0%)
≥ 10 cm
Total sites, n 10 2 7 4 1
Sites failed, n (%) 2 (20%) 0 (0%) 2 (29%) 0 (0%) 0 (0%)
*Crude rates of failure.though 13% had relapsed or refractory disease and 10%
were treated with palliative intent. At a median follow-
up of 5 years, in-field control was similar between the
low and high dose groups (82% vs 83%; HR 1.09,
p = 0.7). Overall, in-field control was lower than that
seen in retrospective series where 5 year rates were
greater than 90% [19,20]. The inferior in-field control in
the UK trial may be explained by inclusion of patients
with refractory disease, 20% of patients receiving RT
alone, and less rigorous radiographic assessment of
chemotherapy response. It has been demonstrated that a
positive post-chemotherapy PET scan compared to a
negative scan predicts for worse 5-year in-field in
patients who receive consolidation RT (71% vs 95%,
p = 0.008) [20].
A retrospective series from the Netherlands suggests
that RT doses less than 30 Gy may be equally effective
in patients who have a complete response to chemother-
apy [19]. This study found excellent in-field control rates
among 94 patients with stage I intermediate-to-high
grade NHL who achieved a complete response on CT
imaging after 4 cycles of CHOP. There was no difference
in 5-year crude in-field control between patients who
received 26 Gy versus 40 Gy (92% vs 95%).
Similar to the study from the Netherlands, we found
excellent 5-year in-field control of 94% among patients
who had a complete response to chemotherapy and
underwent consolidation RT. There was no difference in
IFC among sites that received ≤ 20 Gy versus those that
received 26–30 Gy (94% vs 95%). Our study is unique in
that the majority of patients received R-CHOP (63%)
and underwent functional imaging (89%). In addition,
lower doses of RT were utilized (median, 30 Gy; range,
12–40 Gy).
In contrast to our findings, there was evidence of a RT
dose response in a retrospective series from MD Anderson
of 162 patients with stage I-III DLBCL [21]. Five-year
in-field control was significantly worse for patients who
received< 40 Gy compared with ≥ 40 Gy (83% vs 97%,
p = 0.002). The main limitation of this study is that
chemotherapy response assessment was based on plain
X-ray imaging. Consistent with our study, there was a
higher rate of in-field failure with tumors that were
originally ≥ 10 cm.
A limitation of our study is that it is retrospective and
non-randomized in nature. Further, there were few in-
field failures, which may limit the power to detect a RT
dose response. There was clearly a preference to treat
more advanced stage patients with lower doses of RT.
This may over- or underestimate a RT dose response be-
cause stage III-IV patients are at an overall higher risk of
disease recurrence, but distant failures may eclipse the
importance of in-field failures. We did not find the latter
to be the case in that patterns of failure were similar
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role of consolidation RT in advanced DLBCL is contro-
versial and the benefit of radiation therapy, regardless of
dose, has not been conclusively demonstrated. At DCI,
we are currently treating DLBCL patients who have a
complete response to 4 or more cycles of R-CHOP
based on PET imaging with consolidation RT dose of
18–20 Gy as part of a phase II trial.
Conclusion
In-field control was excellent in DLBCL patients who
have a complete response to chemotherapy and receive
consolidation RT. There were low rates of in-field failure
after consolidation RT, irrespective of dose.
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